Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.41 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | AR | P10275 | 8/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | SYK | P43405 | 1/20 | 0.35 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | KIF11 | P52732 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9235250 | 0.81 | CYP3A4 (0.49) | CYP3A4TRPA1ALDH1A1HPGDTDP1 | |
| SCHEMBL31135862 | 0.80 | CES2 (0.46) | CYP3A4TRPA1ALDH1A1HPGDTDP1 | |
| SCHEMBL10905501 | 0.80 | CES2 (0.46) | CYP3A4TRPA1ALDH1A1HPGDTDP1 | |
| SCHEMBL30438763 | 0.80 | IDO1 (0.39) | CYP3A4TRPA1ALDH1A1HPGDTDP1 | |
| SCHEMBL3104369 | 0.80 | CYP3A4 (0.50) | CYP3A4TRPA1ALDH1A1HPGDTDP1 | |
| SCHEMBL424482 | 0.80 | IDO1 (0.39) | CYP3A4TRPA1ALDH1A1HPGDTDP1 | |
| SCHEMBL12509626 | 0.79 | SMN1; SMN2 (0.38) | ALDH1A1HPGDARSMN1; SMN2SYK | |
| SCHEMBL21921291 | 0.79 | NPC1 (0.41) | CYP3A4ALDH1A1ARSMN1; SMN2SYK | |
| SCHEMBL162277 | 0.79 | RAB9A (0.40) | CYP3A4TRPA1ALDH1A1HPGDTDP1 | |
| SCHEMBL29648862 | 0.79 | RAB9A (0.40) | CYP3A4TRPA1ALDH1A1HPGDTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10107798-B2 | Methods of chemotype evolution | SUNESIS PHARMACEUTICALS, INC. (US) | 2018-10-23 | — | — | US | disclosed |
| US-20180238863-A1 | CHEMICAL SYNTHESIS | SUNESIS PHARMACEUTICALS, INC. (US) | 2018-08-23 | — | — | US | disclosed |
| EP-2257637-B1 | METHODS OF CHEMOTYPE EVOLUTION | SUNESIS PHARMACEUTICALS INC (US) | 2015-09-23 | — | — | EP | disclosed |
| US-20110118126-A1 | METHODS OF CHEMOTYPE EVOLUTION | SUNESIS PHARMACEUTICALS, INC. | 2011-05-19 | — | — | US | disclosed |
| EP-2257637-A1 | METHODS OF CHEMOTYPE EVOLUTION | Sunesis Pharmaceuticals, Inc. (US) | 2010-12-08 | — | — | EP | disclosed |
| WO-2009120795-A1 | METHODS OF CHEMOTYPE EVOLUTION | SUNESIS PHARMACEUTICALS, INC. (US) | 2009-10-01 | — | — | WO | disclosed |
| US-4466966-A | N-aryl-N'-(1,4,5,6-tetrahydropyrimidin-2-yl)ureas for intestinal disorders | MCNEILAB, INC. (US) | 1984-08-21 | — | — | US | disclosed |
| US-4285948-A | ADMINISTERING CARDIOTONIC AGENTS | MCNEILAB, INC. (US) | 1981-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180238863-A1 | CHEMICAL SYNTHESIS | COASY, FASN, DHPS | CYP3A4 136/4885TRPA1 4557/4885ALDH1A1 987/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.